Wire · opportunities
US firm ArriVent's plunge shows risks facing China's biotech expansion into global markets
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 7 October 2026 · Fusion42 review
US-listed biotech firm ArriVent's stock fell nearly 47% after its licensed Chinese lung cancer drug failed a phase 3 trial in a first-line therapy setting, underscoring the challenges Chinese biotech faces in achieving global clinical success beyond their domestic market.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 6 Oct 2026 and 7 Oct 2026.
◆ ◆ The Wire takeaway
Chinese biotech founders exporting drugs globally face a high bar for clinical success beyond China. You need to prepare for tougher scrutiny and potential trial failures as your products enter first-line therapy markets worldwide.
◆ Coverage
2 sources · first reported 6 Oct 2026 · latest 7 Oct 2026
◆ Related on Wire
◆ Topics